Home

Trials

Primary therapie
- Early Stage:
  - HD16 for early stage:
    Treatment optimization trial in the first-line treatment of early stage Hodgkin Lymphoma: Treatment stratification by means of FDG-PET.
- Intermediate Stage:
  - PVAG-14 for intermediate stage:
    A randomized phase II study of prednisone, vinblastine, doxorubicin and gemcitabine in patients with intermediate stage Hodgkin's Lymphoma.
- Advanced Stage:
  - HD18 for advanced stage:
    Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma: treatment stratification by means of FDG-PET.
- Elderly Patients:
  - AVD-Rev for early unfavourable and advanced stages: Phase I trial to determine dose limiting toxicities of lenalidomide in combination with adriamycin, vinblastine and darcabazine for patients between 60 and 75 years.
Rezidivtherapie
- HCD122 by HD and NHL:
  A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin´s or Hodgkin´s lymphoma who have progressed after at least two prior therapies.
- CLBH589E2214:
  A phase II study of oral Panobinostat in adult patients with relapsed/refractory classical Hodgkin´s Lymphoma after failure of high-dose chemotherapie with autologous stem cell transfusion and a Gemcitabine- or Vinorelbine- or Vinblastine-containing treatment regimen.

News

Das 8. Internationale Hodgkin-Symposium wird vom 23.-26.10.2010 im Kölner Gürzenich statt-finden

Die AVD-Rev Studie wurde bei älteren Hodgkin Lymphom Patienten im Alter von ≥ 60 bis ≤ 75 Jahre in mittleren und fortgeschrittenen Stadien ohne jegliche Vorbehandlung gestartet